- Home
- BRIA vs CTMX Comparison
BRIA vs CTMX Comparison
Compare BRIA & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRIA
- CTMX
- Stock Information
- Founded
- BRIA 2011
- CTMX 2008
- Country
- BRIA Singapore
- CTMX United States
- Employees
- BRIA N/A
- CTMX N/A
- Industry
- BRIA
- CTMX Biotechnology: Pharmaceutical Preparations
- Sector
- BRIA
- CTMX Health Care
- Exchange
- BRIA NYSE
- CTMX Nasdaq
- Market Cap
- BRIA 73.0M
- CTMX 62.3M
- IPO Year
- BRIA 2024
- CTMX 2015
- Fundamental
- Price
- BRIA $2.46
- CTMX $0.59
- Analyst Decision
- BRIA
- CTMX Buy
- Analyst Count
- BRIA 0
- CTMX 6
- Target Price
- BRIA N/A
- CTMX $5.77
- AVG Volume (30 Days)
- BRIA 20.3K
- CTMX 3.5M
- Earning Date
- BRIA 03-25-2025
- CTMX 03-06-2025
- Dividend Yield
- BRIA N/A
- CTMX N/A
- EPS Growth
- BRIA N/A
- CTMX N/A
- EPS
- BRIA 92.24
- CTMX 0.38
- Revenue
- BRIA $55,755,669.00
- CTMX $138,103,000.00
- Revenue This Year
- BRIA N/A
- CTMX N/A
- Revenue Next Year
- BRIA N/A
- CTMX N/A
- P/E Ratio
- BRIA $0.03
- CTMX $1.55
- Revenue Growth
- BRIA 8.03
- CTMX 36.45
- 52 Week Low
- BRIA $2.30
- CTMX $0.56
- 52 Week High
- BRIA $4.38
- CTMX $5.85
- Technical
- Relative Strength Index (RSI)
- BRIA N/A
- CTMX 30.34
- Support Level
- BRIA N/A
- CTMX $0.60
- Resistance Level
- BRIA N/A
- CTMX $0.78
- Average True Range (ATR)
- BRIA 0.00
- CTMX 0.06
- MACD
- BRIA 0.00
- CTMX -0.00
- Stochastic Oscillator
- BRIA 0.00
- CTMX 13.69
About BRIA BRILLIA INC
BrilliA Inc is engaged in business of sales and marketing of lingerie's products including bra, panty and body suit, mainly serving the American, European and other markets.
About CTMX CytomX Therapeutics Inc.
CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company that is operating in the United States. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.